Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

BACKGROUND: The randomized phase 3 COMBI-i trial did not meet its primary endpoint of improved progression-free survival (PFS) with spartalizumab plus dabrafenib and trametinib (sparta-DabTram) vs placebo plus dabrafenib and trametinib (placebo-DabTram) in the overall population of patients with unr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawbi, Hussein A, Robert, Caroline, Brase, Jan C, Gusenleitner, Daniel, Gasal, Eduard, Garrett, James, Savchenko, Alexander, Görgün, Güllü, Flaherty, Keith T, Ribas, Antoni, Dummer, Reinhard, Schadendorf, Dirk, Long, Georgina V, Nathan, Paul D, Ascierto, Paolo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214378/
https://www.ncbi.nlm.nih.gov/pubmed/35728875
http://dx.doi.org/10.1136/jitc-2021-004226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214378/
https://www.ncbi.nlm.nih.gov/pubmed/35728875
http://dx.doi.org/10.1136/jitc-2021-004226

Ejemplares similares